ab 6 June 2025 Global Research Drug-related news China Healthcare Weekly recap: EU's market access restrictions for Chinese medtech firms A and H healthcare indices maintained upward trend this week Over 2-6 June, HSHCI rose 4.1% and HSHKBIO rose 4.5%. SW healthcare A/H rose 1.1%/1.9%, ranking 17th/13th among A/H share sectors, with chemicals outperforming both in A (up 1.7%) and H (up 3.8%), mainly due to the positive ASCO data presentations of multiple companies, in our view. Our top picks: Wuxi Apptec an ...

5 June 2025 | 12:27AM HKT Innovent Biologics (1801.HK): ASCO 2025 take: Encouraging survival benefit of IBI363; Better understanding of POC hinges on RCT data As noted in our previous ASCO2025 notes (preview, abstract takeaway), Innovent orally presented the updated ph1 data of IBI363 (PD-1/IL-2α-bias BsAb) in NSCLC, CRC, and melanoma, which we view as incrementally positive for ORR/PFS compared to abstract, with particular highlight on the encouraging survival benefit (OS data debut) in IO-treated squamous ...

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination of sintilimab and fruquint ...